HER2-negative early breast cancer
Key Takeaways in the Management of HER2-Negative Early Breast Cancer

Released: May 08, 2024

Expiration: May 07, 2025

Activity

Progress
1
Course Completed
Key Takeaways
  • Recent trials have altered the treatment landscape of HER2-negative early breast cancer (EBC). 
    • For eligible patients with high-risk hormone receptor (HR)–positive/HER2-negative EBC, adjuvant abemaciclib and olaparib are options.
    • Although not currently approved by the FDA or recommended by the guidelines, adjuvant ribociclib may be considered in specific cases for patients with HR-positive/HER2-negative EBC based on phase III data demonstrating an invasive disease–free survival benefit.
    • In addition to (neo)adjuvant pembrolizumab for triple-negative EBC, adjuvant capecitabine and olaparib are options for eligible patients.
  • Appropriately assessing for recurrence risk is critical in tailoring the treatment plan for an individual patient.
  • Patient education and strategies for adverse event prophylaxis and management are crucial to optimize adherence and outcomes.
  • Go online for more details on these important treatment considerations for patients with HER2-negative EBC. Watch an on-demand webcast and download the associated slides from a recent program.

Your Thoughts?
What challenges do you face with integrating targeted therapy into the care of patients with HER2-negative EBC? Join the discussion by answering the polling question and posting a comment.

Poll

1.

Which of the following topics in HER2-negative EBC would you be interested in learning more about?

Submit